Modality
Bispecific Ab
MOA
BCMA ADC
Target
Menin
Pathway
Lipid Met
SCLCAsthma
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
May 2018
→ May 2031
Phase 2Current
NCT05098494
2,795 pts·SCLC
2021-01→2031-05·Terminated
NCT04987180
2,578 pts·SCLC
2018-05→2030-07·Terminated
5,373 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-07-034.3y awayPh3 Readout· SCLC
2031-05-085.1y awayPh3 Readout· SCLC
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2030-07-03 · 4.3y away
SCLC
Ph3 Readout
2031-05-08 · 5.1y away
SCLC
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05098494 | Phase 2/3 | SCLC | Terminated | 2795 | SRI-4 |
| NCT04987180 | Phase 2/3 | SCLC | Terminated | 2578 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Cevimavacamten | Denali | NDA/BLA | Menin | |
| Tixatapinarof | Recursion | Approved | FGFR |